Valuation: Natera, Inc.

Market Cap 39.3B 34.38B 31.7B 29.33B 55.67B 3,751B 56.6B 380B 149B 1,842B 148B 144B 6,380B P/E 2026 *
-165x
P/E 2027 * -1,154x
Enterprise Value 38.27B 33.48B 30.88B 28.57B 54.22B 3,653B 55.13B 370B 145B 1,794B 144B 141B 6,214B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 11.4x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day+2.43%
1 week+0.63%
Current month+3.54%
1 month+26.14%
3 months+38.46%
6 months+19.96%
Current year+22.69%
1 week 269.66
Extreme 269.66
288.04
1 month 208.79
Extreme 208.794
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

General Counsel

-16,800 0.0117%
06-30Sell

Executive/Senior Manager

-3,000 0.0021%
06-25Free

Director

1,905 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%+0.63%+73.77%+481.81% 39.3B
-0.87%-3.45%+6.95%+31.64% 22.77B
-2.24%+1.81%-20.59%-38.23% 7.46B
-7.36%-4.26%+14.23%+107.57% 5.16B
+1.88%+3.79%+16.99%+42.79% 2.88B
-6.26%+2.73%-24.52%+1,033.25% 1.95B
+3.37%-3.20%+94.89%-13.47% 1.85B
-1.98%-10.54%+24.25%-26.35% 1.68B
+1.82%-0.63%+22.02%-2.73% 1.62B
-0.30%-3.21%-18.66%-69.06% 1.56B
Average +1.05%-1.40%+18.93%+154.72% 8.62B
Weighted average by Cap. +1.12%-0.42%+37.12%+253.68%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.09B 3.96B 267B 4.03B 27.03B 10.6B 131B 10.5B 10.28B 454B 3.33B 2.91B 2.68B 2.48B 4.71B 318B 4.79B 32.14B 12.6B 156B 12.49B 12.22B 540B
Net income -224M -196M -181M -167M -318M -21.39B -323M -2.17B -849M -10.51B -841M -823M -36.39B -27.55M -24.1M -22.22M -20.56M -39.03M -2.63B -39.68M -266M -104M -1.29B -103M -101M -4.47B
Net Debt -1.02B -896M -826M -764M -1.45B -97.73B -1.47B -9.89B -3.88B -47.99B -3.84B -3.76B -166B -1.3B -1.14B -1.05B -973M -1.85B -124B -1.88B -12.59B -4.94B -61.09B -4.89B -4.79B -212B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-09 US$281.26 +2.50% 887,131
26-07-08 US$274.39 -2.45% 1,398,594
26-07-07 US$281.27 -0.89% 1,759,681
26-07-06 US$283.80 +1.60% 1,358,559
26-07-02 US$279.32 +1.10% 1,274,247
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
274.39USD
Average target price
271.24USD
Spread / Average Target
-1.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock